Young Hwa Soung

Dr. Young Hwa Soung

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2004 in Oncogene
Verified
Journal Article
Closed access
JLJong Woo Lee
Jong Woo Lee
YSYoung Hwa Soung
Young Hwa Soung
SKSu Young Kim
Su Young Kim
HLHae Woo Lee
Hae Woo Lee
WPWon Sang Park
Won Sang Park
SLSug Hyung Lee
Sug Hyung Lee

12 January 2017 in Cancers
Verified
Journal Article
Open access
PDF file
YSYoung Hwa Soung
Young Hwa Soung
SFShane Ford
Shane Ford
VZVincent Zhang
Vincent Zhang
JCJun Chung
Jun Chung
Exosomes are endosome derived extracellular vesicles of 30–120 nm size ranges. Exosomes have been identified as mediators of cell-to-cell communication by transferring bioactive molecules such as nucleic acids, proteins and lipids into recipient cells. While exosomes are secreted by multiple cell types, cancer derived exosomes not only influence the invasive potentials of proximally located cells, but also affect distantly located tissues. Based on their ability to alter tumor microenvironment by regulating immunity, angiogenesis and metastasis, there has been growing interest in defining the clinical relevance of exosomes in cancers. In particular, exosomes are valuable sources for biomarkers due to selective cargo loading and resemblance to their parental cells. In this review, we summarize the recent findings to utilize exosomes as cancer biomarkers for early detection, diagnosis and therapy selection.

1 September 2003 in Gastroenterology
Verified
Journal Article
Closed access
HKHong Sug Kim
Hong Sug Kim
JLJong Woo Lee
Jong Woo Lee
YSYoung Hwa Soung
Young Hwa Soung
WPWon Sang Park
Won Sang Park
SKSu Young Kim
Su Young Kim
SLSug Hyung Lee
Sug Hyung Lee

15 April 2005 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJong Woo Lee
Jong Woo Lee
YSYoung Hwa Soung
Young Hwa Soung
SKSu Young Kim
Su Young Kim
HNHyo Kyung Nam
Hyo Kyung Nam
WPWon Sang Park
Won Sang Park
SLSug Hyung Lee
Sug Hyung Lee
Purpose: Recently, the kinase domain mutations of epidermal growth factor receptor (EGFR) gene have been identified in non–small-cell lung cancer, and these mutations have been related to the clinical response to the tyrosine kinase inhibitor gefitinib. Gefitinib treatment has also shown clinical benefits in squamous cell carcinoma of the head and neck (SCCHN). The aim of this study was to explore the possibility that SCCHN harbored the EGFR mutations. Experimental Design: In this study, we analyzed EGFR gene in 41 SCCHN for the detection of the somatic mutations by PCR-single-strand conformational polymorphism analysis. Results: Overall, we detected three EGFR mutations (7.3%), and all of the mutations were the same in-frame deletion mutation in exon 19 (E746_A750del). Conclusion: These data indicated that in addition to non–small-cell lung cancer, SCCHN harbors the EGFR gene mutations, and suggested the rationale for the clinical applicability of gefinitib to SCCHN patients.

1 January 2006 in Clinical Cancer Research
Verified
Journal Article
Closed access
JLJong Woo Lee
Jong Woo Lee
YSYoung Hwa Soung
Young Hwa Soung
SSSi Hyung Seo
Si Hyung Seo
SKSu Young Kim
Su Young Kim
CPCho Hyun Park
Cho Hyun Park
SLSug Hyung Lee
Sug Hyung Lee
Purpose: Recent reports revealed that the kinase domain of the ERBB2 gene is somatically mutated in lung adenocarcinoma, suggesting the mutated ERBB2 gene as an oncogene in human cancers. However, because previous reports focused the mutational search of ERBB2 primarily on lung cancers, the data on ERBB2 mutations in other types of human cancers have been largely unknown. Experimental Design: Here, we did a mutational analysis of the ERBB2 kinase domain by PCR single-strand conformational polymorphism assay in gastric, colorectal, and breast carcinoma tissues. Results: We detected the ERBB2 kinase domain mutations in 9 of 180 gastric carcinomas (5.0%), in 3 of 104 colorectal carcinomas (2.9%), and in 4 of 94 breast carcinomas (4.3%). All of the detected ERBB2 mutations except for one in-frame deletion mutation were missense mutations. Of the 16 ERBB2 mutations detected, 4 affected Val777 in the exon 20 site, and 3 affected Leu755 in the exon 19 site. We simultaneously analyzed the somatic mutations of EGFR, K-RAS, PIK3CA, and BRAF genes in the 16 samples with ERBB2 mutations, and found that all of the 3 colorectal carcinoma samples with ERBB2 mutations harbored K-RAS mutations. Conclusion: This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.

1 February 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
YSYoung Hwa Soung
Young Hwa Soung
JLJong Woo Lee
Jong Woo Lee
SKSu Young Kim
Su Young Kim
JJJin Jang
Jin Jang
YPYong Gyu Park
Yong Gyu Park
SLSug Hyung Lee
Sug Hyung Lee
Several lines of evidence indicate that deregulation of apoptosis is involved in the mechanisms of cancer development. Caspase-8 activation plays a central role in the initiation phase of apoptosis. The aim of this study was to explore the possibility that genetic alteration of CASPASE-8 gene is involved in the development of human cancers, including gastric cancers. We have analyzed the entire coding region of human CASPASE-8 gene for the detection of somatic mutations in 162 gastric carcinomas (40 early and 122 advanced cancers), 185 non–small cell lung cancers, 93 breast carcinomas, and 88 acute leukemias by PCR-single-strand conformation polymorphism. Of the cancers analyzed, 13 cancers harbored CASPASE-8 somatic mutations. Interestingly, all of the mutations were detected in the advanced gastric cancers (10.7% of the 122 samples). We expressed the tumor-derived caspase-8 mutants in 293T, 293, and HT1080 cells and found that most of the mutants (9 of the 10 mutations tested) markedly decreased the cell death activity of caspase-8. In addition, in the cells with the inactivating caspase-8 mutants, cleavage of poly(ADP-ribose)polymerase was markedly reduced compared with that of wild-type caspase-8. The occurrence of CASPASE-8 mutation and the inactivation of cell death activity by the mutants suggest that CASPASE-8 gene mutation may affect the pathogenesis of gastric cancers, especially at the late stage of gastric carcinogenesis.